|
| Press Releases |
|
 |
|
| Friday, May 27, 2022 |
|
|
Legend Capital's Portfolio Company Feima Robotics Assists China's 38th Antarctic Expedition with a Series of Civilian UAV Products |
| On April 26, 2022, the expedition ship Xuelong 2 for China's 38th Antarctic expedition berthed at the Shanghai base dock. So far, China's 38th Antarctic expedition, which lasted 174 days and traveled more than 33,000 nautical miles, has ended successfully. more info >> |
|
| Wednesday, April 27, 2022 |
|
|
Legend Capital's Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis |
| Legend Capital's portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases. more info >> |
|
| Tuesday, April 26, 2022 |
|
|
Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022 |
| Legend Capital's portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO) on the KOSDAQ market, and it plans to submit a registration statement within the second quarter of 2022. more info >> |
|
| Sunday, April 24, 2022 |
|
|
君联资本联合创建企业朗信生物遗传性视网膜变性基因治疗产品在中国获批临床 |
| 君联资本联合创建企业朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣布，公司产品LX101注射液用于治疗RPE65双等位基因突变相关的遗传性视网膜变性（IRD）患者的临床试验申请，已获得中国国家药品监督管理局药品审评中心（CDE）批准。 more info >> |
|
|
君聯資本聯合創建企業朗信生物遺傳性視網膜變性基因治療產品在中國獲批臨床 |
| 君聯資本聯合創建企業朗信生物（Innostellar Biotherapeutics Co.,Ltd）旗下上海朗昇生物科技有限公司宣佈，公司產品LX101注射液用於治療RPE65雙等位基因突變相關的遺傳性視網膜變性（IRD）患者的臨床試驗申請，已獲得中國國家藥品監督管理局藥品審評中心（CDE）批准。 more info >> |
|
|
Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China |
| Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics more info >> |
|
| Thursday, April 7, 2022 |
|
|
君联资本所投创新型疫苗领军企业瑞科生物在港交所成功上市 |
| 3月31日，君联资本所投创新型疫苗领军企业瑞科生物（股票代码：02179.HK）在港交所成功上市。此次在港上市，成为“香港HPV疫苗第一股”、“香港新型佐剂疫苗第一股”的瑞科生物相信将会给香港资本市场注入新的活力。 more info >> |
|
|
君聯資本所投創新型疫苗領軍企業瑞科生物在港交所成功上市 |
3月31日，君聯資本所投創新型疫苗領軍企業瑞科生物（股票代碼：02179.HK）在港交所成功上市。此次在港上市，成為「香港HPV疫苗第一股」、「香港新型佐劑疫苗第一股」的瑞科生物相信將會給香港資本市場注入新的活力。
more info >> |
|
|
Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully |
| On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange. more info >> |
|
| Tuesday, March 8, 2022 |
|
|
从边缘走向舞台中央：君联资本所投生物技术产业链上游专精特新企业的奋斗之路 |
| 据联想控股微空间报导，「专精特新」的灵魂是创新，强调「专精特新」就是要鼓励创新。政策目标在于强化科技创新和产业链供应链韧性，加强基础研究，推动应用研究，开展补链强链专项行动，加快解决「卡脖子」难题。联想控股旗下君联资本不仅有幸参与到众多「专精特新」企业的发展中，也践行着将「前瞻性」及「硬科技」作为关键词的投资理念。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Future of Uncrewed Airpower on Display at Paris Air Show
Jun 16, 2025 00:00 HKT/SGT
|
|
|
無人空中力量的未來在巴黎航展上亮相
Jun 16, 2025 00:00 HKT/SGT
|
|
|
調味品龍頭來襲！海天味業啟動港股招股
Jun 13, 2025 23:14 HKT/SGT
|
|
|
调味品龙头来袭！海天味业启动港股招股
Jun 13, 2025 23:02 HKT/SGT
|
|
|
SAP商業AI持續釋放數據價值 驅動企業韌性增長
Jun 13, 2025 22:52 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Annual Results
Jun 13, 2025 21:49 HKT/SGT
|
|
|
達豐設備服務有限公司公佈2024/25全年業績
Jun 13, 2025 21:38 HKT/SGT
|
|
|
达丰设备服务有限公司公布2024/25全年业绩
Jun 13, 2025 21:34 HKT/SGT
|
|
|
Yee Hop Holdings (1662.HK) Subsidiary APEL Launches Microfactory in Collaboration with HKPC
Jun 13, 2025 20:38 HKT/SGT
|
|
|
義合控股(1662.HK)附屬APEL與生產力局攜手打造智能微工廠正式投產
Jun 13, 2025 20:20 HKT/SGT
|
|
|
义合控股(1662.HK)附属APEL与生产力局携手打造智能微工厂正式投产
Jun 13, 2025 19:42 HKT/SGT
|
|
|
Jacobson Pharma Announces FY2025 Annual Results
Jun 13, 2025 19:16 HKT/SGT
|
|
|
雅各臣公佈二零二五財年全年業績 持續經營業務溢利飈升43.1％至3.0億港元
Jun 13, 2025 19:06 HKT/SGT
|
|
|
Desert Mirage or Musical Revolution? ESCAPE Records' Secret Vault Opens, Revealing a Hidden Sonic Sanctuary
Jun 13, 2025 19:00 HKT/SGT
|
|
|
雅各臣公布二零二五财年全年业绩 持续经营业务溢利飙升43.1％至3.0亿港元
Jun 13, 2025 18:53 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
